aripiprazole + olanzapine

This entry refers to a clinical research study conducted by the Veterans Medical Research Foundation comparing two separate atypical antipsychotic medications, aripiprazole and olanzapine, rather than a single combination product. Aripiprazole is a quinolinone derivative that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, often described as a dopamine stabilizer. Olanzapine is a thienobenzodiazepine that acts as a potent antagonist at multiple receptor sites, including dopamine D1-D4, serotonin 5-HT2A/2C, histamine H1, and muscarinic M1 receptors. The study, titled Acute Impact of IM Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics, was a randomized, double-blind crossover trial evaluating the immediate effects of single intramuscular doses of these medications on insulin sensitivity in non-psychiatric prediabetic men. The research aimed to assess the metabolic side-effect profiles of these agents, particularly their impact on insulin resistance, independent of weight gain or psychiatric disease.